RNU6-982P

Across TCGA pan-cancer cohorts, RNU6-982P RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RNU6-982P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-982P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-982P expression acts as an unfavorable survival marker, although some lineages such as STAD and KIRP show a favorable association.

LIHC, CESC, and SARC are the cancer types where RNU6-982P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	III,IV	0.092	0.649	<.001	78	view →
CESC	OS	Tertile	All	0.098	0.588	.004	72	view →
SARC	OS	Tertile	All	0.065	0.842	<.001	54	view →
THCA	DFS	Tertile	All	0.077	0.811	<.001	45	view →
STAD	OS	Tertile	IV	1.000	0.294	.019	36	view →
PAAD	OS	Tertile	All	0.138	0.590	<.001	27	view →
ESCA	DFS	Tertile	All	0.148	0.673	.040	18	view →
LAML	DFS	Tertile	All	0.195	0.577	.042	18	view →
HNSC	OS	Tertile	IV	0.001	0.643	<.001	18	view →
PRAD	DFS	Tertile	All	0.690	0.887	.038	18	view →
TGCT	DFS	Quartile	All	0.692	0.875	.016	12	view →
KIRP	DFS	Tertile	III,IV	1.000	0.357	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

RNU6-982P–LIHC (OS)

Open the LIHC breakdown →